Lomitapide

(Juxtapid®)

Juxtapid®

Drug updated on 11/16/2023

Dosage FormCapsule (oral; 5 mg, 10 mg, 20 mg, 30 mg)
Drug ClassMicrosomal triglyceride transfer protein inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).